Our top pick for
IDEXX Laboratories, Inc is a diagnostics & research business based in the US. IDEXX Laboratories shares (IDXX) are listed on the NASDAQ and all prices are listed in US Dollars. IDEXX Laboratories employs 9,300 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$472.11|
|52-week range||$280.53 - $573.99|
|50-day moving average||$514.40|
|200-day moving average||$489.42|
|Wall St. target price||$580.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$7.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-05-05)||-10.91%|
|1 month (2021-04-15)||-10.66%|
|3 months (2021-02-12)||-13.23%|
|6 months (2020-11-13)||4.07%|
|1 year (2020-05-15)||60.37%|
|2 years (2019-05-15)||89.18%|
|3 years (2018-05-15)||125.98%|
|5 years (2016-05-13)||444.72%|
Valuing IDEXX Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDEXX Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, IDEXX Laboratories shares trade at around 70x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.6401. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $895.7 million.
The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.9 billion|
|Operating margin TTM||27.92%|
|Gross profit TTM||$1.6 billion|
|Return on assets TTM||23.67%|
|Return on equity TTM||166.25%|
|Market capitalisation||$46.6 billion|
TTM: trailing 12 months
There are currently 738,737 IDEXX Laboratories shares held short by investors – that's known as IDEXX Laboratories's "short interest". This figure is 10.4% down from 824,473 last month.
There are a few different ways that this level of interest in shorting IDEXX Laboratories shares can be evaluated.
IDEXX Laboratories's "short interest ratio" (SIR) is the quantity of IDEXX Laboratories shares currently shorted divided by the average quantity of IDEXX Laboratories shares traded daily (recently around 437122.4852071). IDEXX Laboratories's SIR currently stands at 1.69. In other words for every 100,000 IDEXX Laboratories shares traded daily on the market, roughly 1690 shares are currently held short.
However IDEXX Laboratories's short interest can also be evaluated against the total number of IDEXX Laboratories shares, or, against the total number of tradable IDEXX Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IDEXX Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IDEXX Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0098% of the tradable shares (for every 100,000 tradable IDEXX Laboratories shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IDEXX Laboratories.
Find out more about how you can short IDEXX Laboratories stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.79
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 12/31/2018) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.93/100
IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.44/100
IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 17.91/100
IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||29.79|
|Total ESG percentile||54.84|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months.
IDEXX Laboratories's shares were split on a 2:1 basis on 15 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.
Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as $280.531 up to $573.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 0.885. This would suggest that IDEXX Laboratories's shares are less volatile than average (for this exchange).
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.